Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial

Version 1 : Received: 28 August 2023 / Approved: 29 August 2023 / Online: 31 August 2023 (09:25:35 CEST)

A peer-reviewed article of this Preprint also exists.

Abuogi, L.; Oyaro, P.; Wakjira, G.; Thomas, K.K.; Scallon, A.J.; Mukui, I.; Chohan, B.H.; Brown, E.; Karauki, E.; Yongo, N.; Ahmed, B.; Hassan, S.A.; Wagude, J.; Kinywa, E.; Otieno, L.; Kingwara, L.; Oyaro, B.; Frenkel, L.M.; John-Stewart, G.; Patel, R.C. HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial. Viruses 2023, 15, 2083. Abuogi, L.; Oyaro, P.; Wakjira, G.; Thomas, K.K.; Scallon, A.J.; Mukui, I.; Chohan, B.H.; Brown, E.; Karauki, E.; Yongo, N.; Ahmed, B.; Hassan, S.A.; Wagude, J.; Kinywa, E.; Otieno, L.; Kingwara, L.; Oyaro, B.; Frenkel, L.M.; John-Stewart, G.; Patel, R.C. HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial. Viruses 2023, 15, 2083.

Abstract

Increasing HIV drug resistance (DR) among children with HIV (CHIV) on antiretroviral treatment (ART) is concerning. CHIV ages 1-14 years enrolled March 2019 to December 2020 from five facilities in Kisumu County, Kenya were included. Children were randomized 1:1 to control (standard-of-care) or intervention (point-of-care viral load (POC VL) testing every three months with targeted genotypic drug resistance testing (DRT) for VF (> 1000 copies/ml)). A multidisciplinary committee reviewed CHIV with DRT results and offered treatment recommendations. We describe DR mutations and present logistic regression models to identify factors associated with clinically significant DR. We enrolled 704 children in the study; median age was 9 years (interquartile range (IQR) 7,12), 344 (49%) were female and median time on ART was 5 years (IQR 3, 8). During the study period, 106 (15%) children had DRT results (84 intervention and 22 control). DRT detected mutations associate with DR in all participants tested, with 93 (88%) having major mutations, including 51 (54%) with dual class resistance. A history of VF in prior 2 years (adjusted odds ratio (aOR) 11.1; 95% confidence interval (CI) 6.3, 20.0) and less than 2 years on ART at enrollment (aOR 2.2; 95% CI 1.1, 4.4) were associated with increased odds of major DR. DR is highly prevalent among CHIV on ART with VF in Kenya. Factors associated with drug resistance may be used to determine which children should be prioritized for DRT.

Keywords

HIV; children; drug resistance; virologic failure

Subject

Medicine and Pharmacology, Immunology and Allergy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.